相关实验视频

Updated: May 23, 2025

Direct Measurement of KDM1A Target Engagement Using Chemoprobe-based Immunoassays

Direct Measurement of KDM1A Target Engagement Using Chemoprobe-based Immunoassays

Published on: June 13, 2019

确定KDM5B是KMT2D突变骨肉瘤的合成致命目标

Liyu Yang¹, Jing Zhang², Yiting Jiang³

¹Department of Orthopedics, Shengjing Hospital of China Medical University, Shenyang, Liaoning Province, China.

Chemico-biological interactions

|March 7, 2025

概括

在骨髓瘤 (OS) 中失去KMT2D促进恶性瘤. 向KDM5B提供了一种新的治疗策略,可以选择性地杀死KMT2D缺乏的癌细胞,并在临床前模型中显示出前景.

科学领域:

在瘤学瘤学.
表观遗传学在表观遗传学中,表观遗传学是指表观遗传学.
分子生物学分子生物学

背景情况:

骨髓瘤 (OS) 是青少年常见的骨癌,具有复杂的表观遗传特征.
基因组甲基转移酶KMT2D的功能丧失突变在各种癌症中观察到,包括OS.
KMT2D缺乏与骨髓瘤中恶性表型的促进有关.

研究的目的:

调查KMT2D损失在骨髓瘤进展中的作用.
为了确定KMT2D突变骨肉瘤的潜在治疗点.
评估KDM5B抑制作为合成致命策略的有效性.

主要方法:

对表观遗传抑制剂库进行选,以识别向KMT2D缺乏细胞的化合物.
在KMT2D-Knockout (KO) 和野生类型骨髓瘤细胞中使用shRNA进行KDM5B敲除.
细胞增殖,迁移和细胞亡的评估.
在患者衍生异种移植 (PDX) 鼠标模型中测试KDM5B抑制的有效性和安全性.

主要成果:

KDM5B 抑制剂选择性地杀死了缺乏 KMT2D 的骨髓瘤细胞.
抑制KDM5B减少了增殖和迁移,同时诱导KMT2D-KO细胞的亡.
在KMT2D低骨髓瘤的临床前PDX模型中,KDM5B抑制证明了效率和安全性.

结论:

在KMT2D-loss骨髓瘤中,KDM5B充当合成致命因子.
向KDM5B代表了针对KMT2D突变骨髓瘤的新治疗方法.
这一策略为一组特定的骨髓瘤患者提供了潜在的治疗途径.

关键词:

表观遗传调节表观遗传调节这就是KDM5B.在KMT2D中,KMT2D是KMT2D.骨质肉瘤骨质肉瘤是什么合成致命的致命的合成药物

更多相关视频

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Published on: January 7, 2019

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

M-Cdk Drives Transition Into Mitosis

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...

Abnormal Proliferation

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...

In-vitro Mutagenesis

In-vitro Mutagenesis

To learn more about the function of a gene, researchers can observe what happens when the gene is inactivated or “knocked out,” by creating genetically engineered knockout animals. Knockout mice have been particularly useful as models for human diseases such as cancer, Parkinson’s disease, and diabetes.